One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis

Abstract

We conducted an evaluation of changes in cognition in progressive multiple sclerosis (MS) patients receiving monthly intravenously pulse of cyclophosphamide (700 mg/m²) with methylprednisolone (1 g). Twenty-eight consecutive progressive MS patients (10 primary progressive, 18 secondary progressive MS) were evaluated before and after six and 12 months of treatment. The WAIS-R score, memory and executive functions were evaluated. Under treatment we found a significant improvement in global cognitive efficiency, encoding abilities, planning abilities and inhibition after six and 12 months. However, mechanisms of action of the positive effect of these anti-inflammatory and immunosuppressive treatments on cognition remain unclear.

Keywords

cognitive function cyclophosphamide methylprednisolone progressive multiple sclerosis

Get full access to this article

View all access options for this article.

References

Beatty WW , Paul RH , Wilbanks SL , Hames KA , Blanco CR , Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) . Neurology 1995; 45: 718-723 .

Goodkin DE. Interferon beta therapy for multiple sclerosis . Lancet 1998; 352: 1486-1487 .

Weinstein A , Schwid SIL , Schiffer RB , McDermott MP , Giang DW , Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer . Arch Neurol 1999; 56: 319-324 .

Fischer JS , Priore RL , Jacobs LD , Cookfair DL , Rudick RA , Herndon RM et al. Neuropsychological effects of Interferon b-1a in relapsing multiple sclerosis . Ann Neurol 2000; 48: 885-892 .

Barak Y , Achiron A. Effects of interferon beta-1b on cognitive functions in multiple sclerosis . Eur Neurol 2002; 47: 11-14 .

Thompson AJ , Polman CH , Miller H , McDonald WI , Brochet B , Fillipi M et al. Primary progressive multiple sclerosis . Brain 1997; 120: 1085-1096 .

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

Weiner HL , Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects . Mult Scler 2002; 8: 142-154 .

Kujala P , Portin R , Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up . Brain 1997; 120: 289-297 .

10.

Patzold T , Schwengelbeck M , Ossege LM , Malin JP , Sindern E. Changes of the MS Functional Composite EDSS during and after treatment of relapses with methylprednisolone in patients with MS . Acta Neurol Scand 2002; 105: 164-168 .